Both agents activate the Nrf2-Keap1 pathway, which enhances antioxidant defenses and restores gut barrier integrity
GLP-1 use in this group is presumed to be for the treatment of obesity
For patients currently in compounded GLP-1 programs, the transition would likely involve one of several options: switching to an FDA-approved branded medication (at substantially higher cost), discussing alternative weight management approaches with a licensed provider, or exploring whether 503A patient-specific compounding applies to their individual clinical situation
GLP-1 drugs appear to have direct protective effects on the cardiovascular system, reducing inflammation, improving endothelial function, and potentially stabilizing atherosclerotic plaques
They are all class B1 GPCRs, share significant sequence similarity (Usdin et al., 1993) and form secretin-VIP receptor family ( GIPR Expression The human GIP receptor (GIPR) gene is 13.8 kb long containing 14 exons